Hillstream BioPharma to Present at Noble Capital’s Sixteenth Small and Micro Cap Conference
FEBRUARY 3, 2020
Chester, New Jersey, February 3, 2020 – Hillstream BioPharma Inc. (“Hillstream”) today announced its participation in Noble Capital’s Sixteenth Small and Micro Cap Conference. Hillstream will be providing updates on recent corporate developments as well as outlining near-term activities anticipated in 1H-2020. Details about the conference are as follows:
Hard Rock Hollywood
Sunday, February 16 – Tuesday, February 18, 2020
Monday, February 17, 2020 – 3pm, Terrance Room B
A webcast of the Hillstream presentation will be available on the corporate web site – www.hillstreambio.com.
One-on-one meetings can be arranged during conference through the Noble Conference 1:1 meeting feature. Investors wishing to meet with Hillstream outside of the Noble Conference can book appointments directly through Hillstream’s investor relations representative, Jennifer K. Zimmons, Ph.D. firstname.lastname@example.org or +1.917.214.3514.
About Hillstream BioPharma Inc.
Hillstream BioPharma Inc. (“Hillstream”) is a development-stage company advancing novel immune-oncology therapeutics for critical unmet needs. By harnessing the body’s immune system and Hillstream’s QUATRAMER technology, which reduces off-target effects, Hillstream develops targeted cancer therapies with improved safety and a delivery profile with higher efficacy. Hillstream’s competitive advantage is to enhance the safety and efficacy of oncology therapies by encapsulating them in its proprietary polymeric injectable suspension comprised of FDA-recognized inactive ingredients. Encapsulation ensures delivery within the tumor cells and prevents free drug levels in circulation that can cause toxicity. The slow and sustained release of the therapy may also reduce the frequency of dosing while maintaining its efficacy. The novel QUATRAMER formulation allows Hillstream to build a strong patent estate and seek both FDA Orphan Drug Designation and more rapid FDA review in specific indications. For more information, please visit www.hillstreambio.com.
About Noble Capital Markets, Inc.
Noble Capital Markets (“Noble”) is a research driven boutique investment bank that has supported small & microcap companies since 1984. As a FINRA and SEC licensed broker dealer Noble provides institutional-quality equity research, merchant and investment banking, wealth management and order execution services. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the last decade. In 2018 Noble launched www.channelchek.com – a new investment community dedicated exclusively to small and micro-cap companies and their industries. Channelchek is tailored to meet the needs of self-directed investors and financial professionals. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 6,000 emerging growth companies are listed on the site, with growing content including webcasts, podcasts, and balanced news.
Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, as well as the risks that prior clinical and preclinical results may not be replicated. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.
Hillstream BioPharma Inc.
President & CEO
Hillstream Biopharma Inc.
Tel: +1 302.743.2995
Jennifer K. Zimmons, Ph.D.
Zimmons International Communications
Tel: +1 917.214.3514